Regulation of pituitary tumor transforming gene (PTTG) expression and phosphorylation in thyroid cells

Endocrinology

Volumn 154, Issue 11, 2013, Pages 4408-4422

  Lewy, Gregory D ^a   Ryan, Gavin A ^a   Read, Martin L ^a   Fong, Jim C W ^a   Poole, Vikki ^a   Seed, Robert I ^a   Sharma, Neil ^a   Smith, Vicki E ^a   Kwan, Perkin P K ^a   Stewart, Sarah L ^a   Bacon, Andrea ^a   Warfield, Adrian ^b   Franklyn, Jayne A ^a   McCabe, Christopher J ^a   Boelaert, Kristien ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; ONCOGENE; PITUITARY TUMOR TRANSFORMING GENE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; THYROID CARCINOMA; THYROID CELL; UPREGULATION;

ANIMALS; AUTOCRINE COMMUNICATION; CDC2 PROTEIN KINASE; CELL LINE; CELL PROLIFERATION; CRICETINAE; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULINS; MICE; MICE, TRANSGENIC; PARACRINE COMMUNICATION; PHOSPHORYLATION; SECURIN; THYROID GLAND;

EID: 84886451091     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-2156     Document Type: Article

References (73)

1. Pei L. Pituitary tumor-transforming gene protein associates with ribosomal protein S10 and a novel human homologue of DnaJ in testicular cells. J Biol Chem. 1999;274: 3151-3158.
2. Zhang X, Horwitz GA, Prezant TR, et al. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1999;13: 156-166.
3. Boelaert K, McCabe CJ, Tannahill LA, et al. Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab. 2003;88: 2341-2347.
4. Heaney AP, Nelson V, Fernando M, Horwitz G. Transforming events in thyroid tumorigenesis and their association with follicular lesions. J Clin Endocrinol Metab. 2001;86: 5025-5032.
5. Liang HS, Zhong YH, Luo ZJ, et al. Comparative analysis of protein expression in differentiated thyroid tumours: a multicentre study. J Int Med Res. 2009;37: 927-938.
6. Zatelli MC, Tagliati F, Amodio V, et al. Role of pituitary tumour transforming gene 1 in medullary thyroid carcinoma. Anal Cell Pathol (Amst). 2010;33: 207-216.
7. Sáez C, Martínez-Brocca MA, Castilla C, et al. Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer. J Clin Endocrinol Metab. 2006;91: 1404-1409.
8. Yu R, Ren SG, Horwitz GA, Wang Z, Melmed S. Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Mol Endocrinol. 2000;14: 1137-1146.
9. Zou H, McGarry TJ, Bernal T, Kirschner MW. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science. 1999;285: 418-422.
10. Zur A, Brandeis M. Securin degradation is mediated by fzy and fzr, and is required for complete chromatid separation but not for cytokinesis. EMBO J. 2001;20: 792-801.
11. Jallepalli PV, Waizenegger IC, Bunz F, et al. Securin is required for chromosomal stability in human cells. Cell. 2001;105: 445-457.
12. Kim D, Pemberton H, Stratford AL, et al. Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene. 2005;24: 4861-4866.
13. Wang Z, Yu R, Melmed S. Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol Endocrinol. 2001;15: 1870-1879.
14. Yu R, Heaney AP, Lu W, Chen J, Melmed S. Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J Biol Chem. 2000;275: 36502-36505.
15. Yu R, Lu W, Chen J, McCabe CJ, Melmed S. Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. Endocrinology. 2003;144: 4991-4998.
16. Boelaert K, Yu R, Tannahill LA, et al. PTTG's C-terminal PXXP motifs modulate critical cellular processes in vitro. J Mol Endocrinol. 2004;33: 663-677.
17. Ishikawa H, Heaney AP, Yu R, Horwitz GA, Melmed S. Human pituitary tumor-transforming gene induces angiogenesis. J Clin Endocrinol Metab. 2001;86: 867-874.
18. Kim DS, Franklyn JA, Boelaert K, Eggo MC, Watkinson JC, McCabe CJ. Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/ kinase insert domain receptor/inhibitor ofDNAbinding-3 autocrine pathway. J Clin Endocrinol Metab. 2006;91: 4603-4611.
19. McCabe CJ, Boelaert K, Tannahill LA, et al. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab. 2002; 87: 4238-4244.
20. Chamaon K, Kanakis D, Mawrin C, Dietzmann K, Kirches E. Transcripts of PTTG and growth factors bFGF and IGF-1 are correlated in pituitary adenomas. Exp Clin Endocrinol Diabetes. 2010;118: 121-126.
21. KimDS, Franklyn JA, Stratford AL, Boelaert K, Watkinson JC, Eggo MC, McCabe CJ. Pituitary tumor-transforming gene regulates mul-tiple downstream angiogenic genes in thyroid cancer. J Clin Endocrinol Metab. 2006;91: 1119-1128.
22. Ying H, Suzuki H, Furumoto H, Walker R, Meltzer P, Willingham MC, Cheng SY. Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma. Carcinogenesis. 2003;24: 1467-1479.
23. Kim CS, Ying H, Willingham MC, Cheng SY. The pituitary tumortransforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer. Carcinogenesis. 2007;28: 932-939.
24. Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med. 1999;5: 1317-1321.
25. Heaney AP, Fernando M, Melmed S. Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest. 2002;109: 277-283.
26. Chamaon K, Kirches E, Kanakis D, Braeuninger S, Dietzmann K, Mawrin C. Regulation of the pituitary tumor transforming gene by insulin-like-growth factor-I and insulin differs between malignant and non-neoplastic astrocytes. Biochem Biophys Res Commun. 2005;331: 86-92.
27. Thompson AD 3rd, Kakar SS. Insulin and IGF-1 regulate the expression of the pituitary tumor transforming gene (PTTG) in breast tumor cells. FEBS Lett. 2005;579: 3195-3200.
28. Tfelt-Hansen J, Yano S, Bandyopadhyay S, Carroll R, Brown EM, Chattopadhyay N. Expression of pituitary tumor transforming gene (PTTG) and its binding protein in human astrocytes and astrocytoma cells: function and regulation of PTTG in U87 astrocytoma cells. Endocrinology. 2004;145: 4222-4231.
29. Vlotides G, Cruz-Soto M, Rubinek T, Eigler T, Auernhammer CJ, Melmed S. Mechanisms for growth factor-induced pituitary tumor transforming gene-1 expression in pituitary folliculostellate TtT/GF cells. Mol Endocrinol. 2006;20: 3321-3335.
30. Tsai SJ, Lin SJ, Cheng YM, Chen HM, Wing LY. Expression and functional analysis of pituitary tumor transforming gene-1 [corrected] in uterine leiomyomas. J Clin Endocrinol Metab. 2005; 90: 3715-3723.
31. published correction appears in J Clin Endocrinol Metab. 2005;90:5233
32. Clem AL, Hamid T, Kakar SS. Characterization of the role of Sp1 and NF-Y in differential regulation of PTTG/securin expression in tumor cells. Gene. 2003;322: 113-121.
33. Kakar SS, Jennes L. Molecular cloning and characterization of the tumor transforming gene (TUTR1): a novel gene in human tumorigenesis. Cytogenet Cell Genet. 1999;84: 211-216.
34. Wang Z, Melmed S. Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. J Biol Chem. 2000;275: 7459-7461.
35. Zhou Y, Mehta KR, Choi AP, Scolavino S, Zhang X.DNAdamageinduced inhibition of securin expression is mediated by p53. J Biol Chem. 2003;278: 462-470.
36. Pei L. Genomic organization and identification of an enhancer element containing binding sites for multiple proteins in rat pituitary tumor-transforming gene. J Biol Chem. 1998;273: 5219-5225.
37. Chintharlapalli S, Papineni S, Lee SO, et al. Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins. Mol Carcinog. 2011;50: 655-667.
38. Milanini-Mongiat J, Pouysségur J, Pagès G. Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J Biol Chem. 2002;277: 20631-20639.
39. Pore N, Liu S, Shu HK, et al. Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell. 2004;15: 4841-4853.
40. Ramos-Morales F, Domínguez A, Romero F, et al. Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product. Oncogene. 2000;19: 403-409.
41. Pei L, Melmed S. Isolation and characterization of a pituitary tumortransforming gene (PTTG). Mol Endocrinol. 1997;11: 433-441.
42. Abbud RA, Takumi I, Barker EM, et al. Early multipotential pituitary focal hyperplasia in the α-subunit of glycoprotein hormonedriven pituitary tumor-transforming gene transgenic mice. Mol Endocrinol. 2005;19: 1383-1391.
43. El-Naggar SM, Malik MT, Martin A, et al. Development of cystic glandular hyperplasia of the endometrium in Mullerian inhibitory substance type II receptor-pituitary tumor transforming gene transgenic mice. J Endocrinol. 2007;194: 179-191.
44. Fong MY, Farghaly H, Kakar SS. Tumorigenic potential of pituitary tumor transforming gene (PTTG) in vivo investigated using a transgenic mouse model, and effects of cross breeding with p53+/- transgenic mice. BMC Cancer. 2012;12:532.
45. Boelaert K, Smith VE, Stratford AL, et al. PTTG and PBF repress the human sodium iodide symporter. Oncogene. 2007;26: 4344-4356.
46. Eggo MC, King WJ, Black EG, Sheppard MC. Functional human thyroid cells and their insulin-like growth factor-binding proteins: regulation by thyrotropin, cyclic 3',5' adenosine monophosphate, and growth factors. J Clin Endocrinol Metab. 1996;81: 3056-3062.
47. Stratford AL, Boelaert K, Tannahill LA, et al. Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis. J Clin Endocrinol Metab. 2005;90: 4341-4349.
48. Read ML, Lewy GD, Fong JC, et al. 2011 Proto-oncogene PBF/ PTTG1IP regulates thyroid cell growth and represses radioiodide treatment. Cancer Res. 2011;71: 6153-6164.
49. Smith VE, ReadML,Turnell AS, et al.Anovel mechanism of sodium iodide symporter repression in differentiated thyroid cancer. J Cell Sci. 2009;122: 3393-3402.
50. James SR, Franklyn JA, Reaves BJ, et al. Monocarboxylate transporter 8 in neuronal cell growth. Endocrinology. 2009;150: 1961-1969.
51. Bacon A, Kerr NC, Holmes FE, Gaston K, Wynick D. Characterization of an enhancer region of the galanin gene that directs expression to the dorsal root ganglion and confers responsiveness to axotomy. J Neurosci. 2007;27: 6573-6580.
52. Hogan B, Beddington R, Constantini F, Lacey E. Manipulating the Mouse Embryo: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1994.
53. Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005; 65: 4238-4245.
54. Ballester M, Castelló A, Ibáñez E, Sánchez A, Folch JM. Real-time quantitative PCR-based system for determining transgene copy number in transgenic animals. Biotechniques. 2004;37: 610-613.
55. Wang Z, Moro E, Kovacs K, Yu R, Melmed S. Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes. Proc Natl Acad Sci U S A. 2003; 100: 3428-3432.
56. Clarke WE, Berry M, Smith C, Kent A, Logan A. Coordination of fibroblast growth factor receptor 1 (FGFR1) and fibroblast growth factor-2 (FGF-2) trafficking to nuclei of reactive astrocytes around cerebral lesions in adult rats. Mol Cell Neurosci. 2001;17: 17-30.
57. Jeker LT, Hejazi M, Burek CL, Rose NR, Caturegli P. Mouse thyroid primary culture. Biochem Biophys Res Commun. 1999;257: 511-515.
58. Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene. 2008;27(Suppl 1):S71-S83.
59. Khandanpour C, Phelan JD, Vassen L, et al. Growth factor independence 1 antagonizes a p53-inducedDNAdamage response pathway in lymphoblastic leukemia. Cancer Cell. 2013;23: 200-214.
60. Yeh MW, Rougier JP, Park JW, et al. Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptordependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocr Relat Cancer. 2006;13: 1173-1183.
61. Lam AK, Lau KK, Gopalan V, Luk J, Lo CY. Quantitative analysis of the expression of TGF-α and EGFR in papillary thyroid carcinoma: clinicopathological relevance. Pathology. 2011;43: 40-47.
62. Landriscina M, Pannone G, Piscazzi A, et al. Epidermal growth factor receptor 1 expression is upregulated in undifferentiated thyroid carcinomas in humans. Thyroid. 2011;21: 1227-1234.
63. Lee DH, Lee GK, Kong SY, et al. Epidermal growth factor receptor status in anaplastic thyroid carcinoma. J Clin Pathol. 2007;60: 881-884.
64. Chen RN, Huang YH, Yeh CT, Liao CH, Lin KH. Thyroid hormone receptors suppress pituitary tumor transforming gene 1 activity in hepatoma. Cancer Res. 2008;68: 1697-1706.
65. Pei L. Activation of mitogen-activated protein kinase cascade regulates pituitary tumor-transforming gene transactivation function. J Biol Chem. 2000;275: 31191-31198.
66. Chesnokova V, Kovacs K, Castro AV, Zonis S, Melmed S. Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis. Mol Endocrinol. 2005;19: 2371-2379.
67. Mu YM, Oba K, Yanase T, et al. Human pituitary tumor transforming gene (hPTTG) inhibits human lung cancer A549 cell growth through activation of p21(WAF1/CIP1). Endocr J. 2003;50: 771-781.
68. Yu R, Cruz-Soto M, Li Calzi S, Hui H, Melmed S. Murine pituitary tumor-transforming gene functions as a securin protein in insulinsecreting cells. J Endocrinol. 2006;191: 45-53.
69. Boelaert K, Tannahill LA, Bulmer JN, et al. A potential role for PTTG/securin in the developing human fetal brain. FASEB J. 2003; 17: 1631-1639.
70. Wang Z, Melmed S. Characterization of the murine pituitary tumor transforming gene (PTTG) and its promoter. Endocrinology. 2000; 141: 763-771.
71. Cho-Rok J, Yoo J, Jang YJ, et al. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology. 2006;43: 1042-1052.
72. Lai Y, Xin D, Bai J,MaoZ,NaY. The important anti-apoptotic role and its regulation mechanism of PTTG1 in UV-induced apoptosis. J Biochem Mol Biol. 2007;40: 966-972.
73. Maiorano E, Ciampolillo A, Viale G, et al. Insulin-like growth factor 1 expression in thyroid tumors. Appl Immunohistochem Mol Morphol. 2000;8: 110-119.